公开(公告)号：US20240139302A1

公开(公告)日：2024-05-02

申请号：US17801099

申请日：2021-02-22

申请人： Origimm Biotechnology GmbH

发明人： Sanja Selak ,  Christine Triska ,  Manfired Schuster ,  Johannes Söllner ,  Bernhard Roppenser ,  Theresa Weinhäupl ,  Max Rössler

IPC分类号： A61K39/05 ,  A61P17/10 ,  A61P31/04 ,  C07K14/195

CPC分类号： A61K39/05 ,  A61P17/10 ,  A61P31/04 ,  C07K14/195

摘要： The present invention discloses a vaccine comprising one or more of Dermatan sulfate-binding adhesin 1 of P. acnes (DsA1 polypeptide), Dermatan sulfate-binding adhesin 2 of P. acnes (DsA2 polypeptide), and putative iron-transport protein (PITP) polypeptide of P. acnes, and/or a fragment and/or derivative of DsA1 and/or DsA2 and/or PITP, wherein the DsA1 polypeptide and the DsA2 polypeptide comprise from N- to C-terminus an N-terminal swapping region (“NSR”), a first conserved sub-domain (“CSD1”), a first swapping region (“SR1”), a second conserved sub-domain (“CSD2”), a second swapping region (“SR2”), a third conserved sub-domain (“CSD3”), a Pro-Thr repeat containing region (“PT repeat region”), and a C-terminal region (“CTR”), and wherein the PITP polypeptide comprises from N- to C-terminus an extended neocarzinostatin family domain (“ENFD”), a first swapping region (“SR1”), a heme-binding domain (“HbD”), a second swapping region (“SR2”) including the C-terminal LPXTG motif, and a hydrophobic C-terminal region (“hLAR”).

公开(公告)号：US11692229B2

公开(公告)日：2023-07-04

申请号：US17033034

申请日：2020-09-25

申请人： The Regents of the University of California

发明人： Huiying Li ,  Shuta Tomida ,  Robert L. Modlin ,  Jeffery F. Miller ,  Sorel T. Fitz-Gibbon

IPC分类号： C12Q1/689 ,  C12Q1/6883 ,  A61K39/05 ,  A61K35/741 ,  A61K35/76 ,  A61K39/02 ,  C12N7/00 ,  C12Q1/70

CPC分类号： C12Q1/689 ,  A61K35/741 ,  A61K35/76 ,  A61K39/0208 ,  A61K39/05 ,  C12N7/00 ,  C12Q1/6883 ,  C12Q1/701 ,  C12N2795/00032 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/16

摘要： Methods of diagnosing and treating patients afflicted with acne, including diagnosing one as having acne if the individual possesses RT4, RT5, RT7, RT8, RT9, or RT10. Methods for treating acne include administering an effective amount of a drug specifically targeting RT4, RT5, RT7, RT8, RT9, or RT10, such as small molecules, antisense molecules, siRNAs, biologics, antibodies, phages, vaccines, or combination thereof.

公开(公告)号：US11680087B2

公开(公告)日：2023-06-20

申请号：US17126712

申请日：2020-12-18

申请人： Pfizer Inc.

发明人： Annaliesa Sybil Anderson ,  Rasappa Gounder Arumugham ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Kathrin Ute Jansen ,  Thomas Richard Jones ,  Lakshmi Khandke ,  Bounthon Loun ,  John Lance Perez ,  Gary Warren Zlotnick

IPC分类号： A61K39/05 ,  C07K14/22 ,  A61K39/00 ,  A61K39/13 ,  A61K39/295 ,  A61K39/095 ,  A61K39/12 ,  A61K39/39 ,  C12N7/00

CPC分类号： C07K14/22 ,  A61K39/0016 ,  A61K39/095 ,  A61K39/12 ,  A61K39/13 ,  A61K39/295 ,  A61K39/39 ,  C12N7/00 ,  A61K2039/5252 ,  A61K2039/545 ,  A61K2039/55505 ,  A61K2039/55511 ,  A61K2039/70 ,  C12N2710/20034 ,  C12N2770/32634 ,  Y02A50/30

摘要： In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in SEQ ID NO: 1 and a second polypeptide having the sequence set forth in SEQ ID NO: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in SEQ ID NO: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in SEQ ID NO: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mM histidine, and about 150 mM sodium chloride. In one embodiment, a dose of the composition is about 0.5 ml in total volume. In one embodiment, two-doses of the composition induce a bactericidal titer against diverse heterologous subfamily A and subfamily B strains in a human.

公开(公告)号：US11517596B2

公开(公告)日：2022-12-06

申请号：US17037173

申请日：2020-09-29

申请人： CHAMBIO CO., LTD.

发明人： Meei-Yn Lin ,  Hung-Pin Chiu ,  Yi-Heng Chiu

IPC分类号： A61K35/747 ,  A61K35/745 ,  A61K39/09 ,  A61K39/05 ,  A61P19/02 ,  A61K47/36 ,  A61K47/42 ,  A61K35/00

摘要： A method for alleviating arthritis includes administering to a subject in need thereof a postbiotic extract. The postbiotic extract is prepared by a process including the steps of providing a first material having a first isoelectric point ranging from pH 1 to pH 6 and a second material having a second isoelectric point ranging from pH 4 to pH 8, admixing the first material and a probiotic microorganism with water having a pH greater than the second isoelectric point, so as to forma mixture, adding the second material into the mixture and then adjusting a pH of the second material-added mixture to between the first and second isoelectric points so that a precipitate is formed, and subjecting the precipitate to a cell wall isolation treatment to obtain the postbiotic extract.

公开(公告)号：US11473093B2

公开(公告)日：2022-10-18

申请号：US17518960

申请日：2021-11-04

申请人： Eligo Bioscience

发明人： Aymeric Leveau ,  Inès Canadas Blasco ,  Aurélie Mathieu ,  Antoine Decrulle

IPC分类号： A61P17/10 ,  C12N15/76 ,  C12N15/11 ,  A61K39/02 ,  A61K39/05 ,  C12N9/22 ,  A61K39/00

摘要： The invention relates to C. acnes strains carrying DNA vectors for the production of recombinant C. acnes phages. The invention encompasses a C. acnes producer cell carrying DNA vectors, with a template for recombination with C. acnes phage genome leading to the insertion of a gene of interest, for the production of recombinant phages that can lead to the transgene expression into C. acnes infected by the recombinant phage. The invention encompasses, C. acnes strains containing these vectors, C. acnes recombinant phages and methods of using these recombinant phages.

公开(公告)号：US11273212B2

公开(公告)日：2022-03-15

申请号：US16348803

申请日：2017-11-10

申请人： Sumitomo Dainippon Pharma Co., Ltd. ,  NATIONAL UNIVERSITY CORPORATION EHIME UNIVERSITY

发明人： Akihisa Fukushima ,  Takafumi Tsuboi ,  Eizo Takashima ,  Hikaru Nagaoka

IPC分类号： A61K39/015 ,  A61P33/06 ,  A61K39/05 ,  A61K39/13 ,  C07K14/445 ,  C07K16/20 ,  C12N15/10

摘要： The present invention relates to a polypeptide consisting of an amino acid sequence selected from: (a) the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, (b) an amino acid sequence that differs from the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8 by substitution, deletion, addition, or insertion of 1 to 10, preferably 1-5, more preferably 1, 2 or 3 amino acids, and (c) an amino acid sequence that has at least 95%, preferably 97%, more preferably 99% sequence identity with the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 8, and a malaria vaccine comprising the polypeptide, for example.

公开(公告)号：US20210401961A1

公开(公告)日：2021-12-30

申请号：US17342893

申请日：2021-06-09

申请人： DCPRIME B.V.

发明人： Erik Hans MANTING ,  Satwinder Kaur SINGH ,  Vinod SOMMANDAS

IPC分类号： A61K39/05 ,  A61P35/00

摘要： A method for treating a tumor or generating an immune response against a tumor in a subject in need including a vaccination step comprising administration of a first composition, and a tumor-marking step comprising administration of a second composition, is provided. The first and second composition each comprises an antigenic polypeptide (e.g., a non-tumor antigen) or a nucleic acid encoding an antigenic polypeptide. Also provided are antigenic polypeptides and compositions for use in methods described herein.

公开(公告)号：US20210299237A1

公开(公告)日：2021-09-30

申请号：US16604867

申请日：2018-04-13

申请人： ADJUVANCE TECHNOLOGIES, INC.

发明人： Amanda CHAN ,  Jeffrey GARDNER ,  Lars NORDSTROEM ,  William WALKOWICZ ,  J Tyler MARTIN ,  Weidong Zhang

IPC分类号： A61K39/00 ,  C07H1/08 ,  C07H15/18 ,  A61K39/05 ,  A61K39/08 ,  A61K39/09 ,  A61K39/02 ,  A61K39/29 ,  A61K39/39 ,  A61P31/20 ,  A61P31/04

摘要： The present application relates to triterpene glycoside saponin-derived adjuvants, syntheses thereof, and intermediates thereto. The application also provides pharmaceutical compositions comprising compounds of the present invention and methods of using said compounds or compositions in the treatment of and immunization for infectious diseases.

公开(公告)号：US20210228701A1

公开(公告)日：2021-07-29

申请号：US17228004

申请日：2021-04-12

申请人： Biogen MA Inc.

发明人： Vissia Viglietta

IPC分类号： A61K39/09 ,  A61K39/05 ,  A61K31/225

摘要： Provided herein is a method of treating or preventing a disease or disorder (e.g., MS) in a subject in need thereof, comprising (a) administering to the subject a first dose of a pharmaceutical composition comprising a fumarate agent (e.g., DMF) for a first dosing period; (b) administering a vaccine; and (c) administering to the subject a second dose of the pharmaceutical composition for a second dosing period.

公开(公告)号：US10925906B2

公开(公告)日：2021-02-23

申请号：US16092778

申请日：2017-04-12

申请人： Meiji Co., Ltd.

发明人： Satoshi Kusuda ,  Satsuki Totsu ,  Masaki Terahara

IPC分类号： A61K35/745 ,  A61K39/05 ,  A23L33/135 ,  A23L33/00

摘要： An object of the present invention is to provide a brain function improving agent for neonates, especially, newborn neonates. According to the present invention, there is provided a brain function improving agent for neonates, comprising a lactic acid bacterium and/or a Bifidobacterium. The brain function improving agent or composition for improving brain function for neonates according to the present invention is advantageous in that the use thereof can improve the developmental quotient without any side effect and also enables effective development and growth of neonates.